Publicaciones (80) Publicaciones en las que ha participado algún/a investigador/a

2024

  1. CLO24-079: Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents (ESAs)

    Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 22, Núm. 25

  2. Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT)

    Cytotherapy

  3. Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes

    Nature Communications, Vol. 15, Núm. 1

  4. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet, Vol. 403, Núm. 10423, pp. 249-260

  5. Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee

    eClinicalMedicine, Vol. 69

  6. Ligamentum flavum hematoma: A rare cause of cauda equina syndrome in older old patient

    Revista Espanola de Geriatria y Gerontologia, Vol. 59, Núm. 2

  7. Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification

    British Journal of Haematology, Vol. 204, Núm. 4, pp. 1529-1535

2023

  1. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study

    The Lancet Haematology, Vol. 10, Núm. 2, pp. e117-e128

  2. Autologous mesenchymal stem cell transplantation for spinal fusion: 10 years follow-up of a phase I/II clinical trial

    Stem cell research & therapy, Vol. 14, Núm. 1, pp. 78

  3. Autologous mesenchymal stromal cells embedded with Tissucol Duo® for prevention of air leak after anatomical lung resection: results of a prospective phase I/II clinical trial with long-term follow-up

    Stem Cell Research and Therapy, Vol. 14, Núm. 1

  4. Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE)

    Bone Marrow Transplantation, Vol. 58, Núm. 6, pp. 659-666

  5. Cell and gene therapy workforce development: the role of the International Society for Cell & Gene Therapy (ISCT) in the creation of a sustainable and skilled workforce in Europe

    Cytotherapy, Vol. 25, Núm. 10, pp. 1033-1036

  6. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

    Blood

  7. Effect of hip hemiarthroplasty dislocation on mortality after hip fracture surgery

    Revista Espanola de Cirugia Ortopedica y Traumatologia, Vol. 67, Núm. 1, pp. 3-11

  8. Effects of Dietary Supplementation with a Ferulic Acid-Rich Bioactive Component of Wheat Bran in a Murine Model of Graft-Versus-Host Disease

    Nutrients, Vol. 15, Núm. 21

  9. Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice

    Leukemia and Lymphoma, Vol. 64, Núm. 3, pp. 679-690

  10. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

    Blood

  11. Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study

    Annals of Hematology, Vol. 102, Núm. 2, pp. 311-321

  12. Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion

    Cancer Medicine, Vol. 12, Núm. 16, pp. 16788-16792

  13. LABOR, ECONOMIC, AND CLINICAL FUNCTIONAL IMPACT OF LUMBAR ARTHRODESIS

    Revista de la Asociacion Espanola de Especialistas en Medicina del Trabajo, Vol. 32, Núm. 2, pp. 131-140